New York, USA, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Rich Insights into the Metastatic Urothelial Carcinoma Clinical Trial Analysis Featuring 40+ Companies and Therapies | DelveInsight
Metastasis is the leading cause of cancer-related treatment failure and cancer-related deaths. The rising occurrence of metastatic urothelial carcinoma and increasing research and development activities are the factors driving the market for metastatic urothelial carcinoma. There are several companies developing potential therapies, including Ectin Research AG, 4D pharma plc, Lurbinectedin, and several others.
DelveInsight’s 'Metastatic Urothelial Carcinoma Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline metastatic urothelial carcinoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the metastatic urothelial carcinoma pipeline domain.
Key Takeaways from the Metastatic Urothelial Carcinoma Pipeline Report
- DelveInsight’s metastatic urothelial carcinoma pipeline report depicts a robust space with 35+ active players working to develop 40+ pipeline therapies for metastatic urothelial carcinoma treatment.
- Key metastatic urothelial carcinoma companies such as Ectin Research AG, Eli Lilly and Company, Astellas Pharma Inc, Seagen Inc., Shanghai Miracogen Inc., Advaxis, Inc., 4D pharma plc, Taiho Oncology, Shanghai Miracogen Inc., Exelixis, AstraZeneca, Incyte Corporation, IO Biotech, Jazz Pharmaceuticals, Ectin Research AB, Inovio Pharmaceuticals, Janssen Research & Development, LLC, Sumitomo Pharma Oncology, Bayer, Nurix Therapeutics, Ikena Oncology, XNK Therapeutics AB, Nektar Therapeutics, Tyra Biosciences, Inc., ALX Oncology, Scholar Rock, Inc., Jounce Therapeutics, Inc., and others are evaluating new drugs for metastatic urothelial carcinoma to improve the treatment landscape.
- Promising metastatic urothelial carcinoma pipeline therapies in various stages of development include MFA 370, XL 092, Lurbinectedin, Ramucirumab, AGS15E, Ipilimumab, MRG002, ADXS-NEO, Cabozantinib, MRx0518, Futibatinib, MRG002, Cabozantinib, Tremelimumab, 4D pharma plc, AZD6738, MRx0518, Retifanlimab, IO102-IO103, Lurbinectedin, MFA-370, ABSK-091, INO-5401, Erdafitinib, DSP-7888, Rogaratinib, NX-1607, IK-175, Disitamab Vedotin, NKTR-255, TYRA-300, SRK-181, Vopratelimab, and others.
- In June 2022, XNK Therapeutics AB announced it is initiating a program targeting urothelial cancer, the most common form of bladder cancer. The company will collaborate with the Karolinska University Hospital to initially evaluate XNK’s autologous NK cell product, alone and in combination with existing treatment, on tumor cells from patients with locally advanced or metastatic urothelial cancer with the goal to take this further into a clinical trial.
- In April 2022, Astellas Pharma Inc. and Seagen Inc. announced that the European Commission (EC) had approved PADCEV (enfortumab vedotin) as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and a PD-1/L1 inhibitor. The EC approval is supported by data from the global phase III EV-301 trial that demonstrated an overall survival (OS) benefit compared with chemotherapy.
- In July 2022, the US Food and Drug Administration (FDA) cleared TYRA to proceed with its Phase I/II SURF301 clinical study of TYRA-300 under its Investigational New Drug application (IND), in patients with metastatic urothelial carcinoma of the bladder and urinary tract.
- In June 2022, ALX Oncology Holdings Inc., announced clinical program updates for its lead program, evorpacept, a next generation CD47 blocker. ALX Oncology will initiate a new clinical study, ASPEN-07, to investigate evorpacept in combination with an antibody-drug conjugate (“ADC”), PADCEV® (enfortumab vedotin-ejfv), for the treatment of patients with urothelial carcinoma (“UC”) in the fourth quarter of 2022.
Request a sample and discover the recent advances in metastatic urothelial carcinoma treatment drugs @Metastatic Urothelial Carcinoma Pipeline Report
The metastatic urothelial carcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage metastatic urothelial carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the metastatic urothelial carcinoma clinical trial landscape.
Metastatic Urothelial Carcinoma Overview
Urothelial carcinoma is the sixth most common cancer in the United States. These cancers begin in the urothelial cells that line the bladder's interior. Urothelial cells also line other parts of the urinary tract, including the renal pelvis (the part of the kidney that connects to the ureter), the ureters, and the urethra. Common metastatic urothelial cancer symptoms may include urine pain or burning and a change in urinary habits. This can include frequent urination or the need to urinate but being unable to do so.
Systemic chemotherapy is the standard approach for the initial metastatic urothelial carcinoma treatment of patients with inoperable locally advanced or metastatic urothelial malignancies. Despite high initial response rates, the median survival with multiagent chemotherapy is about 15 months. While this is better than the estimated six-month survival rate with the metastatic disease before the development of modern chemotherapy regimens, the 5-year metastatic urothelial carcinoma survival rate with modern regimens is around 15%.
Find out more about metastatic urothelial carcinoma treatment drugs @Drugs for Metastatic Urothelial Carcinoma Treatment
A snapshot of the Metastatic Urothelial Carcinoma Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Lurbinectedin | Jazz Pharmaceuticals | Phase II | Alkylating agents; DNA damage stimulants | Intravenous |
| MRG002 | Shanghai Miracogen Inc. | Phase II | Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants | Intravenous |
| MRx0518 | 4D pharma plc | Phase II | Bacteria replacements; NF-kappa B modulators; Toll-like receptor 5 agonists | Oral |
| Cabozantinib | Exelixis | Phase II | Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c met inhibitors | Oral |
| MFA 370 | Ectin Research AG | Phase I/II | NA | Oral |
| TYRA-300 | Tyra Biosciences, Inc | Phase I/II | Type 3 fibroblast growth factor receptor antagonists | Oral |
| IK-175 | Ikena Oncology | Phase I | Aryl hydrocarbon receptor antagonists | Oral |
| ALX 148 | ALX Oncology | Preclinical | CD47 antigen inhibitors; Cytotoxic T lymphocyte stimulants; Dendritic cell stimulants; Phagocyte stimulants | Intravenous |
Learn more about the emerging metastatic urothelial carcinoma pipeline therapies @Metastatic Urothelial Carcinoma Clinical Trials
Metastatic Urothelial Carcinoma Therapeutics Assessment
The metastatic urothelial carcinoma pipeline report proffers an integral view of metastatic urothelial carcinoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Metastatic Urothelial Carcinoma Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
- Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
- Therapeutics Assessment By Mechanism of Action: Alkylating agents; DNA damage stimulants, CD47 antigen inhibitors; Cytotoxic T lymphocyte stimulants; Dendritic cell stimulants; Phagocyte stimulants, Type 3 fibroblast growth factor receptor antagonists, Aryl hydrocarbon receptor antagonists, Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants.
- Key Metastatic Urothelial Carcinoma Companies: Ectin Research AG, Eli Lilly and Company, Astellas Pharma Inc, Seagen Inc., Shanghai Miracogen Inc., Advaxis, Inc., 4D pharma plc, Taiho Oncology, Shanghai Miracogen Inc., Exelixis, AstraZeneca, Incyte Corporation, IO Biotech, Jazz Pharmaceuticals, Ectin Research AB, Inovio Pharmaceuticals, Janssen Research & Development, LLC, Sumitomo Pharma Oncology, Bayer, Nurix Therapeutics, Ikena Oncology, XNK Therapeutics AB, Nektar Therapeutics, Tyra Biosciences, Inc., ALX Oncology, Scholar Rock, Inc., Jounce Therapeutics, Inc. and others
- Key Metastatic Urothelial Carcinoma Pipeline Therapies: MFA 370, XL 092, Lurbinectedin, Ramucirumab, AGS15E, Ipilimumab, MRG002, ADXS-NEO, Cabozantinib, MRx0518, Futibatinib, MRG002, Cabozantinib, Tremelimumab, 4D pharma plc, AZD6738, MRx0518, Retifanlimab, IO102-IO103, Lurbinectedin, MFA-370, ABSK-091, INO-5401, Erdafitinib, DSP-7888, Rogaratinib, NX-1607, IK-175, Disitamab Vedotin, NKTR-255, TYRA-300, SRK-181, Vopratelimab, and others.
Dive deep into rich insights for new drugs for metastatic urothelial carcinoma treatment, visit @Metastatic Urothelial Carcinoma Medications
Table of Contents
| 1. | Metastatic Urothelial Carcinoma Pipeline Report Introduction |
| 2. | Metastatic Urothelial Carcinoma Pipeline Report Executive Summary |
| 3. | Metastatic Urothelial Carcinoma Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Metastatic Urothelial Carcinoma Clinical Trial Therapeutics |
| 6. | Metastatic Urothelial Carcinoma Pipeline: Late Stage Products (Pre-registration) |
| 7. | Metastatic Urothelial Carcinoma Pipeline: Late Stage Products (Phase III) |
| 8. | Metastatic Urothelial Carcinoma Pipeline: Mid Stage Products (Phase II) |
| 8.1 | Lurbinectedin: Jazz Pharmaceuticals |
| 9. | Metastatic Urothelial Carcinoma Pipeline: Early Stage Products (Phase I) |
| 9.1 | IK-175: Ikena Oncology |
| 10. | Metastatic Urothelial Carcinoma Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Metastatic Urothelial Carcinoma Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Metastatic Urothelial Carcinoma Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the metastatic urothelial carcinoma pipeline therapeutics, reach out @Metastatic Urothelial Carcinoma Treatment Drugs
Related Reports
Metastatic Urothelial Carcinoma Market
Metastatic Urothelial Carcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic urothelial carcinoma companies including Novaliq GmbH, Kowa, D. Western Therapeutics Institute, Sun Pharma Advanced Research Company, among others.
Metastatic Urothelial Carcinoma Epidemiology Forecast
Metastatic Urothelial Carcinoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted metastatic urothelial carcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Urothelial Carcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key urothelial carcinoma companies including MedPacto, AstraZeneca, Bayer, Vyriad, Seagen, Pfizer, among others.
Urothelial Carcinoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key urothelial carcinoma companies, including MedPacto, AstraZeneca, Bayer, Vyriad, Seagen, Pfizer, among others.
Bladder Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bladder cancer companies, including RemeGen Co., Ltd., Taiho Oncology, Inc., Xennials Therapeutics, Flame Biosciences, among others.
Bladder Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bladder cancer companies, including CG Oncology, FKD Therapies, Bristol-Myers Squibb, LintonPharm Co., Ltd., ImmunityBio, Inc., Hamlet Pharma AB, Asieris Pharmaceuticals, among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Report | Crows Feet Market | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market | Insulin Glargine Biosimilar Insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
